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Abstract
ΔNp63, also known as p40, regulates stemness of normal mammary gland epithelium and provides stem cell charac-
teristics in basal and HER2-driven murine breast cancer models. Whilst ΔNp63/p40 is a characteristic feature of nor-
mal basal cells and basal-type triple-negative breast cancer, some receptor-positive breast cancers express ΔNp63/p40
and its overexpression imparts cancer stem cell-like properties in ER+ cell lines. However, the incidence of ER+ and
HER2+ tumours that express ΔNp63/p40 is unclear and the phenotype of ΔNp63/p40+ cells in these tumours remains
uncertain. Using immunohistochemistry with p63 isoform-specific antibodies, we identified a ΔNp63/p40+ tumour cell
subpopulation in 100 of 173 (58%) non-triple negative breast cancers and the presence of this population associated
with improved survival in patients with ER−/HER2+ tumours (p = 0.006). Furthermore, 41% of ER+/PR+ and/or HER2+
locally metastatic breast cancers expressed ΔNp63/p40, and these cells commonly accounted for <1% of the meta-
static tumour cell population that localised to the tumour/stroma interface, exhibited an undifferentiated phenotype
and were CD44+/ALDH−. In vitro studies revealed that MCF7 and T47D (ER+) and BT-474 (HER2+) breast cancer cell
lines similarly contained a small subpopulation of ΔNp63/p40+ cells that increased in mammospheres. In vivo, MCF7
xenografts contained ΔNp63/p40+ cells with a similar phenotype to primary ER+ cancers. Consistent with tumour
samples, these cells also showed a distinct location at the tumour/stroma interface, suggesting a role for paracrine fac-
tors in the induction or maintenance of ΔNp63/p40. Thus, ΔNp63/p40 is commonly present in a small population of
tumour cells with a distinct phenotype and location in ER+ and/or HER2+ human breast cancers.
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Introduction
The human TP63 gene encodes two major variants that
differ in their N-terminal sequences, with TAp63 con-
taining a p53-like transactivation domain and ΔNp63
(also known as p40) lacking this domain. ΔNp63/p40
is an important stem cell regulator in the epidermis and
glandular epithelial tissues and is crucial for normal
development of these tissues [1–3]. In normal adult
breast, p63 is expressed exclusively in myoepithelium
and initial studies in neoplasia led to the suggestion that
p63 (predominantly ΔNp63/p40) is a marker of
© 2019 The Authors The Journal of Pathology: Clinical Research published by The Pathological
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oestrogen receptor negative (ER−), basal, squamous and
metaplastic breast carcinomas [4–7]. Nevertheless, the
role of p63 in breast malignancy remains unclear.
Breast cancer cells exhibit substantial phenotypic het-
erogeneity, including subpopulations of cells with stem
cell-like properties, termed cancer stem cells (CSCs; also
called cancer-initiating cells). Recent studies have
highlighted the plasticity and heterogeneity of breast
CSCs, where different CSC types exist within and
between tumours [8–13] and each subtype has a different
effect on survival [8,11]. In particular, two distinct breast
CSC types have been reported and classed as luminal
versus basal, or as epithelial versus mesenchymal,
defined by reciprocal expression of MM1 and CD271, or
of aldehyde dehydrogenase (ALDH) and CD44, respec-
tively [9,10]. In addition to the presence of CD44 and
lack of ALDH, mesenchymal-like CSCs occupy a peri-
stromal location, whereas ALDH+/CD44− epithelial-like
CSCs are located more centrally within the tumour [10].
With regard to p63 in breast cancer, ΔNp63/p40 pro-
motes or maintains stem cell activities in murine models
of triple negative breast cancer (TNBC) and human epi-
dermal growth factor receptor 2 (HER2)-driven basal
cancer [14–16]. ΔNp63/p40 also induces CSC-like prop-
erties when overexpressed in luminal breast cancer cell
lines in vitro [17,18] and has been associated with the
CD271+ population of basal-type CSCs in luminal breast
cancers and cell lines [9]. In clinical samples, high level
p63 is characteristic for basal-like TNBCs, where
ΔNp63/p40 regulates EGFR, basal differentiation and
adhesion, and TAp63 associates with androgen receptor,
PTEN mutation and improved survival [19–24]. p63 is
also present in some ER+ and/or HER2+ cancers,
although at lower levels than in TNBCs [4–6] and
ΔNp63/p40+ cells have been reported to be unrelated to
or to associate with a basal-like phenotype [9,20]. The
incidence of ER+/HER2+ cancers that contain a ΔNp63/
p40+ tumour cell subpopulation is also uncertain, partly
due to the presence of ΔNp63/p40 in normal
myoepithelium, which is a common component of surgi-
cally removed human breast cancers [4,25,26]. In this
study, we used clinical samples and cell line models to
re-investigate the incidence of p63 and its isoforms in
human breast cancer. We also investigated the phenotype
of these cells and their relationship with CSC subtypes.
Materials and methods
Human breast cancer samples
In compliance with the Declaration of Helsinki, per-
mission for the use of anonymised excess human
tissues was approved following local ethical commit-
tee review (the Tissue Access Committees at the
Tayside Tissue Bank, Dundee, UK and the Biobank of
clinical samples at the Masaryk Memorial Cancer
Institute, Brno, Czech Republic). Tissue samples com-
prised axillary lymph node metastatic deposits of
33 consecutive ductal breast carcinomas diagnosed in
Brno with metastasis greater than 2 mm in size
(at least pN1) and tissue microarrays (TMAs) of unse-
lected primary breast cancer tissues from patients in
Dundee who had not received treatment before sur-
gery. Tissues used for TMAs and patient characteris-
tics including TP53 mutation status and
immunochemical characterisation following REMARK
guidelines are provided in references [27,28]. In total,
212 tumours were analysed, comprising 39 triple-
negative cancers and 173 ER+ and/or HER2+ cancers.
Cell culture and treatments
MCF7 (and derivative lines LCC1 and LCC9), T47D,
CAMA-1 and ZR-75-1 (ER+/HER2−); SK-BR-3
(HER2+) and BT-474 (ER+/HER2+); TNBC cell
lines BT-20, BT-549, HCC1806, MDA-MB-157,
MDA-MB-231, MDA-MB-453, MDA-MB-468 and
PMC-42; and non-transformed MCF10A cells (basal
phenotype) and FaDu (squamous cell carcinoma) were
obtained from ATCC, ECACC or DSMZ. Cells were
grown at 37 C with 5% CO2 in high glucose DMEM
or McCoys 5A (for SKBR3), each with 10% fetal
bovine serum (all from Invitrogen, Paisley, UK).
MEBM with growth supplements (SingleQuots;
Lonza, Slough, UK) was used for MCF10A. Cells
were split regularly when approximately 80% conflu-
ent and all assays were performed when cells were
subconfluent.
For mammosphere growth, cells were detached by
trypsin and single suspensions prepared by passing
through a 21G needle at least five times. Cells were
counted and checked for doublets in a haemocytometer
and 5000 cells/cm2 were plated in dishes pre-coated
with 1% poly(2-hydroxy-ethyl-methacrylate) (Sigma-
Aldrich, Dorset, UK) in 90% ethanol. Cells were
grown in standard mammosphere culture conditions;
serum-free DMEM/F12 (Invitrogen) containing B27
(Invitrogen) and SingleQuots growth factor supple-
ments (Lonza) [11].
Tumour xenografts
Formalin fixed paraffin embedded tissue blocks of
MCF7 and MDA-MB-231 cells were available from
previous xenograft studies [29]. In brief, cells had
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been injected subcutaneously in female nu/nu immu-
nocompromised mice (Harlan, Loughborough, UK).
MCF7 xenografts were supplemented with slow
release 17β-estradiol pellets (0.72 mg per pellet; Inno-
vative Research of America, FL, USA). Tumours were
excised, fixed in 10% formalin overnight and
processed into paraffin wax using the same procedures
as human tissue samples. Animal procedures were car-
ried out under project licences 60/3405 and 60/3729
according to the guidelines of the UKCCCR.
Reverse transcription-quantitative PCR
RNA was extracted from 5 × 106 cultured cells and
DNA removed by on-column DNase digestion
(RNeasy; Qiagen, West Sussex, UK). RNA integrity
and concentrations were determined using an Agilent
2100 Bioanalyser (Agilent Technologies, Stockport,
UK) before cDNA synthesis from 1 μg RNA using ran-
dom primers and AffinityScript reverse transcriptase
(Agilent). QuantiTect SYBR Green PCR with UNG
treatment (Qiagen) was used for amplification and
quantification in a Mx3005P QPCR System (Agilent)
during 40 PCR cycles. Data were analysed using
MxPro QPCR software (Agilent). Changes in mRNA
levels were calculated using the 2−ΔΔCt method with
GAPDH as the reference gene using primers from
Qiagen QuantiTect Primer Assay. Primers for TP63
isoforms (see supplementary material, Table S1) were
custom synthesised (Sigma-Aldrich).
Western blotting
Cells were lysed in 150 mM NaCl, 1% NP-40, 50 mM
Tris pH 8.0, 5 mM EDTA containing protease inhibitor
cocktail (Sigma-Aldrich) and protein concentrations
measured by Bradford assay (Bio-Rad Laboratories,
Watford, UK). Cell lysates were separated by SDS-
PAGE, blotted onto nitrocellulose membranes and pro-
bed with antibodies to p63 using standard conditions.
Antibodies to actin (AC-40, Sigma) were used as load-
ing controls. Detection employed secondary peroxidase-
labelled anti-rabbit or anti-mouse (Dako, Agilent)
followed by enhanced chemiluminescence (Amersham
ECL; Fisher Scientific, Loughborough, UK).
Immunostaining and scoring
Cultured cells grown on sterilised glass slides were
fixed in −20 C acetone/methanol (1:1) for 10 min
and stored at −80 C. Alternatively, cells or
mammospheres were collected by centrifugation, fixed
in formalin overnight, resuspended in agarose and
processed to paraffin wax. Cell phenotyping used
immunohistochemistry with primary antibodies to p63,
epithelial membrane antigen (EMA, also called
MUC1), ER-alpha, ALDH and CD44 (see supplemen-
tary material, Table S2). Immunostaining for p63
employed monoclonal antibodies that recognise all
p63 isoforms (pan-p63 antibody, clone 6.1), an
isoform-specific TAp63 monoclonal (clone 4.1), and a
monoclonal antibody (clone ΔNp63-1.1) or affinity-
purified polyclonal sera specific for ΔNp63/p40. The
specificity of these antibodies for their respective pro-
tein isoforms and lack of cross-reactivity with the
related p53 and p73 proteins has been demonstrated
previously [21,22,30,31]. Single-labelling used dia-
minobenzidine (DAB) (Sigma-Aldrich) as chromogen
with haematoxylin counterstaining. For dual staining,
nickel sulphate/DAB (blue/grey) was used to detect
the first antigen and the second antigen was detected
with DAB (brown). Sections were either counter-
stained with nuclear fast red or left unstained. For
immunofluorescence, primary antibodies from differ-
ent species were applied together and detected with
secondary fluorochrome-conjugated goat anti-rabbit
and goat anti-mouse (Invitrogen). Samples were
mounted with ProLong Gold (Invitrogen) or
Vectashield (Vector Laboratories, Peterborough, UK)
with DAPI (40,6-diamidino-2-phenylindole) counter-
stain. Controls comprised sections/cells exposed to
either antibody singly but detected with both second-
ary reagents.
In the cohort of metastatic tumours, percentages of
positive cells were estimated for ER, progesterone
receptor (PR), Ki67 and p63, with CD44 and ALDH
as markers of mesenchymal or epithelial CSCs, respec-
tively [9,10]. In TMAs, ER and PR were scored using
the QuickScore [32], where percentage of cells is
graded from 1 to 6 and intensity from 0 to 3, with per-
centage score × intensity score recorded to give values
ranging from 0 to 18. ER+ tumours are defined as hav-
ing a QuickScore >3 [27]. For Ki67, only percentage
was recorded (range 0–6). Samples were divided into
categories of low, medium or high Ki67+ cells, using
three different cut-offs to define low (QuickScore
1 [0–4%], QuickScore 2 [0–19%] or QuickScore
3 [0–40%] and QuickScore >4 [60–100%]) to define
high Ki67. In both sets of samples, HER2 immuno-
staining was scored on the clinically relevant scale of
0–3, with scores of 2 or 3 being subjected to in situ
hybridisation to assess gene amplification.
Statistical tests
Experimental data were obtained from three indepen-
dent repeats. Quantitative immunostaining data were
3ΔNp63/p40 in luminal-type breast cancer
© 2019 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res 2019
obtained by counting the percentages of positive cells
in at least 10 high-power microscope fields. Two-tailed
Student’s t-test was used for cell culture and Mann–
Whitney U test for xenograft data due to the uneven
and non-random distribution of positive cells in
tumour samples. Comparison of clinical data
employed chi-square, or Kaplan–Meier and Mantel–
Cox log-rank tests for survival analyses. P values
<0.05 were considered significant.
Results
ΔNp63/p40+ cells are commonly present in
luminal-type human breast carcinomas
p63, specifically ΔNp63/p40, is present in the nuclei
of normal basal/myoepithelial cells and pan-p63 or
ΔNp63/p40 antibodies are therefore used as a clinical
marker to distinguish invasive from in situ lesions
[4–7,25,26]. To investigate the incidence and pheno-
type of ΔNp63/p40+ tumour cells in human breast car-
cinomas, we initially examined regional (axillary)
lymph node metastases, where contaminating myo-
epithelial cells will not be present, with pan-p63,
TAp63 and ΔNp63/p40 antibodies. Overall, 3 of
6 (50%) metastatic TNBCs and 11 of 27 (41%)
receptor-positive tumours showed p63+ nuclei in a
subpopulation of tumour cells, including 7 of 22 ER+
and/or PR+ tumours and 5 of 6 HER2+ cancers
(including the ER+/HER2+ cancer). Staining was seen
using pan-p63 and ΔNp63/p40 antibodies, but TAp63
was not seen in tumour cells (occasional lymphocytes
were pan-p63+ and TAp63+, as previously reported
[24,30]). Less than 2% of the malignant cells were
ΔNp63/p40+ in 8 of the 11 positive ER+ or HER2+
tumours, with 5 to 15% in the other three (see supple-
mentary material, Table S3). Thus, using a standard
cut-off of 10% positive cells, only 2 of 33 (6%) of
these tumours would be classified as ‘p63-positive’.
ΔNp63/p40+ cells were preferentially located at the
tumour/stroma interface in metastatic deposits
(Figure 1A–F). Dual-labelling indicated that ΔNp63/
p40+ cells were not positive for smooth muscle actin
(SMA), a reliable marker of cancer-associated myo-
epithelial cells [25], and were EMA− (a luminal epi-
thelial differentiation marker) and ER−/weak in ER+
cancers (Figure 1B–D). We also examined two
markers of breast CSC subtypes, CD44 and ALDH.
These markers varied from 0 to 90% of tumour cells
in different tumours (see supplementary material,
Table S3). ΔNp63/p40+ cells were never ALDH+, but
a subset of CD44+ cells were ΔNp63/p40+ (Figure 1E,
F). There were no associations between the presence
of a ΔNp63/p40+ population and the number of nodes
involved, tumour grade, extent of tubule formation, or
proliferation measured by Ki67 or mitotic counts (see
supplementary material, Table S3).
We subsequently used double-staining of ΔNp63/
p40 and SMA on TMAs of primary breast cancer tis-
sues from patients who had not received therapy prior
Figure 1. ΔNp63/p40 in human locally metastatic ER+ luminal
breast cancer. (A) Immunohistochemistry for ΔNp63/p40 shows
nuclear staining (brown) of a subpopulation of tumour cells in a
local lymph node. Nuclei are counterstained with haematoxylin
(blue). Three ΔNp63/p40+ cells are indicated by arrows. (B,C)
Double-labelling immunohistochemistry for ΔNp63/p40 (blue/
grey) and (B) EMA (brown) or (C) SMA (brown). Arrows indicate
ΔNp63/p40+ cells. (D) Immunofluorescence for ΔNp63/p40 (red)
and ER (green) with DAPI counterstain (blue). The arrow indicates
a ΔNp63/p40+ cell. (E) CD44 (blue/grey) and ΔNp63/p40 (brown).
The red arrows indicate two adjacent cells that are CD44+ and
ΔNp63/p40+, the black arrow indicates a CD44+ ΔNp63/p40−
cell. (F) ALDH (brown) and ΔNp63/p40 (blue/grey). Arrows indi-
cate ΔNp63/p40+ or ALDH+ cells. Scale bar = 50 μm.
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to surgery. Only ΔNp63/p40+ cells that were SMA−
were scored to exclude contaminating myoepithelial
cells in these primary tumours. Of the 212 samples
with sufficient tumour available for analysis, 173 were
ER+ and/or HER2+, of which 100 (57.8%) contained
at least one identifiable ΔNp63/p40+/SMA− tumour
cell. As with metastatic deposits, these cells were often
seen at the edge of tumour cell islands.
Within the cohort of 173 receptor-positive tumours,
the presence of a p63/p40+/SMA− cell population did
not correlate with HER2 status, TP53 mutation,
tumour grade, lymph node status, proliferation using
different Ki67 cut-offs, or Nottingham prognostic
index (NPI), but patients were more likely to be dis-
ease free at the time of last follow up (Table 1).
Kaplan–Meier plots and log-rank tests indicated that
patients containing at least one ΔNp63/p40+/SMA−
tumour cell showed a more favourable outcome
(p = 0.032). Sub-grouping indicated that the effect on
survival was confined to ER−/HER2+ cancers (n = 31;
p = 0.006), with no statistically significant associations
in patients with ER+/HER2− or ER+/HER2+ tumours
(Figure 2).
ΔNp63/p40α is expressed in some luminal-type
breast cancer cell lines and increases in
mammosphere cultures
To investigate whether any receptor-positive breast can-
cer cell lines contain a similar population of ΔNp63/p40+
cells, we initially studied publicly available RNA-Seq
data of human cancer cell lines (https://www.ebi.ac.uk/
arrayexpress E-MTAB-2706), containing data for
68 human breast cancer cell lines (see supplementary
material, Figure S1). These analyses revealed that the
highest TP63 mRNA levels (comparable to a squamous
carcinoma of the tongue cell line, FaDu) are seen in the
basal cell lines HCC1806 and MCF10 series, although
not all basal-type lines show high levels (shown in green
in supplementary material, Figure S1). TP63 mRNA was
also seen at low levels in some ER+ and HER2+ cell
lines (see supplementary material, Figure S1). Similarly,
we detected high levels of p63 in MCF10A (basal non-
malignant) and HCC1806 (basal carcinoma) cells by
western blotting using a pan-p63 and a ΔNp63/p40 spe-
cific antibody, at levels comparable to FaDu cells. All
other cells tested were not positive by western blotting
(see supplementary material, Figure S2A).
However, these data measure average mRNA or pro-
tein levels and do not discount the possibility that a small
subpopulation of cells contain detectable levels of p63.
We therefore used a combination of immunostaining and
RT-qPCR as a sensitive and specific method to detect
TP63 mRNA and to identify the specific mRNA
isoforms. We identified variable levels of TP63 mRNAs
in two ER+ cell lines, MCF7 and T47D and in MCF10A
cells (Figure 3A; note the different scales for the y axes).
ΔNp63 mRNA forms predominated over TAp63 (TAp63
was not detected in MCF7 or MCF10A and was 75-fold
lower than ΔNp63 in T47D cells). For C-terminal
isoforms, p63α predominated in all three cell lines, with
much lower levels of p63β and p63γ (Figure 3A). We
then used immunocytochemistry to study p63 isoforms
in cell lines. The majority of HCC1806 and MCF10A
cells were positive using pan-p63 and ΔNp63/p40 anti-
bodies (see supplementary material, Figure S2B), in
keeping with the western blotting and RNA-Seq data.
We also demonstrated the presence of pan-p63 and
ΔNp63/p40 in the nuclei of a small subpopulation of the
ER+ cell lines, MCF7 (4%) and T47D (0.01%), and in
the ER−/HER2+ BT-474 cell line (0.1%) (Figures 3B
and S2B). The ER+ MCF7 cell line derivatives, LCC1
and LCC9 also showed pan-p63 and ΔNp63/p40
staining, similar to MCF7. The other cell lines tested
did not contain pan-p63+ or ΔNp63/p40+ cells (BT-20,
Table 1. Clinical, pathological and immunohistochemical data of
173 untreated primary ER+ and/or HER2+ breast carcinomas
studied by TMA
ΔNp63/
p40− (n = 73)
ΔNp63/
p40+ (n = 100)
P
value




TP53 mutant 17 20 0.740
TP53 wt 56 80
Grades 1–2 45 59 0.729







Ki67 < 20% 20 35 0.411
Ki67 20–60% 47 55
Ki67 > 60% 4 8
With disease 26 21 0.0497
Disease free 47 79
NPI ≤ 2.4 6 9 0.997
NPI 2.41–3.4 12 16
NPI 3.41–5.4 35 50
NPI > 5.4 17 23
ΔNp63/p40+ cancers are defined as having at least one tumour cell that is
ΔNp63/p40+ but SMA−. ER; positive for ER but not HER2. ERH; positive for
both ER and HER2. H; positive for HER2 but negative for ER. HER2, positive for
HER2 (=ERH + H); Values for Ki67 represent the percentage of tumour cells
positive for Ki67 antigen; statistical significance was determined by chi-square
test. Data are shown for only one of the Ki67 cut-offs; using <5% or <40% to
define low Ki67 also indicated lack of statistical significance.
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BT-549, CAMA-1, MDA-MB-157, MDA-MB-231,
MDA-MB-453, MDA-MB-468, PMC-42, SK-BR-3 and
ZR-75-1). Staining was not seen using TAp63 specific
antibody in any of the cell lines tested.
To assess whether ΔNp63/p40 is involved in stem
cell phenotypes in receptor-positive breast cancer cell
lines, we also stained MCF7 and T47D cells grown as
suspension spheroids (Figure 3C,D) (in our hands,
BT-474 cells do not form true mammospheres but
exist in suspension as loose cell aggregates, similar to
some other breast cancer cell lines [11]). The percent-
ages of ΔNp63/p40+ cells increased in both MCF7
and T47D cells when grown as mammospheres com-
pared to monolayers (Figure 3E; p < 0.001 for each).
ΔNp63/p40 marks a distinct subpopulation of
MCF7 cells in vivo
Immunohistochemistry of MCF7 tumour xenografts
demonstrated a small subpopulation of ΔNp63/p40+ cells
throughout the tumour, often clustered together and close
to the tumour/stroma interface (Figure 4A; see supple-
mentary material, Figure S3 for additional examples of
xenograft staining). MDA-MB-231 xenografts did not
show any pan-p63+ or ΔNp63/p40+ cells, in keeping
with their absence in monolayer cultures. Similar to pre-
vious data from ER+ tumours, although the majority of
MCF7 xenograft tumour cells were stained for the lumi-
nal marker EMA, less than 5% of the ΔNp63/p40+ cells
were EMA+ (Figure 4B; see supplementary material,
Figure S4B). ΔNp63/p40+ cells were often closely asso-
ciated with SMA+ host stromal cells but were not them-
selves SMA+ and ΔNp63/p40 was present in a
subpopulation (45.4  8.2%) of CD44+ cells (Figure 4C,
D; see supplementary material, Figure S3C,D). ΔNp63/
p40+ cells were either negative or weakly stained for ER
(Figure 4E–G). ALDH staining was not seen in MCF7
tumour xenografts, although this antibody identifies a
subset of tumour cells and stromal cells in clinical mate-
rial (see Figure 1).
Figure 2. Kaplan–Meier plots of survival according to the presence or absence of ΔNp63/p40+ tumour cells in ER+/HER2+ breast cancers.
Tumours were divided into those that contain a ΔNp63/p40+ population of SMA− cancer cells (p63+; blue lines) and those in which this
population was not seen (p63−; red lines) and correlated with disease-specific survival. ER, ERH and H, tumours that are positive for ER
or HER2, either singly or in combination (n = 173); ER only, tumours that are ER+ and HER2− (n = 142); ER and ERH, tumours that are
ER+/HER2− or ER+/HER2+ (n = 158); HER2-positive, HER2+ tumours that are ER+ or ER− (n = 31). P values are Mantel–Cox log-rank test.
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Discussion
Given the roles of ΔNp63/p40 in maintaining mam-
mary stem/progenitor populations during normal
development and in experimental breast cancers
[14–18] and the occasional reports of pan-p63 and
ΔNp63/p40 in some non-TNBCs [5,9,18,20,33–35],
we re-investigated p63 in human breast cancer. Pan-
p63 or ΔNp63/p40 antibodies are useful marker of nor-
mal myoepithelium to identify benign lesions and dis-
criminate invasive from in situ cancers in clinical
material [4,26], which complicates the analysis of p63
in tumour cells of primary breast cancers. In particular,
occasional pan-p63 or ΔNp63/p40+ cells at the tumour
periphery may represent myoepithelium rather than
neoplastic cells. On the other hand, CSCs often exist
Figure 3. ΔNp63/p40 in luminal breast cancer cell lines. (A) RT-qPCR data of the indicated TP63 mRNA isoforms in MCF7, T47D and
MCF10A cells. Values are given as relative levels normalised to GAPDH. Note that the y axes have different scales and are logarithmic to
show the low levels of TAp63, p63β and p63γ mRNAs (error bars are SD of three independent experiments). (B–D) Representative images
of immunohistochemical staining for ΔNp63/p40 in the indicated cells grown as monolayers under standard culture conditions (B) or as
mammospheres (C,D). Arrows in (B) indicate ΔNp63/p40 positive cells. Scale bar = 50 μm for B–D. (E) Mean percentages of MCF7 and
T47D cells that stain for ΔNp63/p40 grown as monolayer cells or as mammospheres (error bars are 95% confidence intervals of
30 spheroids from three independent experiments).
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at very low frequency [36–38] and may be localised in
specific cell niches, including the tumour periphery
[8–10,13].
To avoid these problems, we initially examined
locally metastatic tumours (which should not contain
non-neoplastic myoepithelium) and found that 41% of
ER+, PR+ or HER2+ cancers contained pan-p63+ and
ΔNp63/p40+ cells, but not TAp63+ cells. The neoplas-
tic nature of these cells was confirmed by their nuclear
morphology. These cells were always a minor popula-
tion (most commonly 1% or less) and were distributed
non-randomly within the metastatic tumours, predomi-
nantly at the tumour/stroma interface. We subse-
quently assessed TMAs of primary non-TNBCs using
Figure 4. Localisation and phenotypic characterisation of ΔNp63/p40-positive cells in MCF7 xenografts. Immunostaining of MCF7 cells
grown as xenografts. (A) ΔNp63/p40 (p63) localisation to the nuclei of tumour cells adjacent to the tumour/stroma interface (ΔNp63/
p40 in brown with haematoxylin counterstain). (B–D) Dual immunoperoxidase staining for (B) ΔNp63/p40 (p63, blue/grey) and EMA
(brown); (C) ΔNp63/p40 (p63, brown) and SMA (blue/grey); (D) ΔNp63/p40 (p63, brown) and CD44 (blue/grey); no counterstain was
used. (E–G) Immunofluorescence for ER in green (E) and ΔNp63/p40 (p63) in red (F). (G) The merged image with DAPI counterstain.
Arrows indicate ΔNp63/p40+ cells. Scale bar = 50 μm.
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double-labelling for SMA and ΔNp63/p40 to avoid
identifying contaminating basal/myoepithelial cells.
More than 50% of these contained a ΔNp63/p40+
SMA− subpopulation, sometimes represented by a sin-
gle cell in one of the TMA cores. These data indicate
that ΔNp63/p40+ tumour cells are common in
receptor-positive breast cancers, but are usually pre-
sent at a very low frequency, unlike basal-type TNBCs
which often contain high numbers of ΔNp63/p40+
cells [7,9,19,20,24]. We also found that two ER+/
HER2− lines (MCF7 and T47D) and BT-474 cells
(ER−/HER2+) show a small population of ΔNp63/p40+
cells, suggesting that these may be useful models to
investigate the role of ΔNp63/p40 in these breast can-
cer subtypes.
In addition to determining incidence, we also investi-
gated the phenotype of ΔNp63/p40+ cells in clinical
samples and cell line models of ER+ and HER2+ breast
cancer. Double-labelling indicated that the ΔNp63/p40+
subpopulation lacked the luminal differentiation
markers ER and EMA, in keeping with a relatively
undifferentiated cell type within these tumours. In terms
of stem cell markers, ΔNp63/p40 identified a subpopu-
lation of CD44+ cells and were consistently negative
for ALDH in patient samples and MCF7 xenografts.
This pattern is similar to the ‘basal-like’ breast CSC
population identified by Kim et al based on expression
of the basal marker CD271 and lack of the luminal dif-
ferentiation marker MM1 [9], and to the ‘mesenchy-
mal-like’ rather than ‘epithelial-like’ CSCs of Liu and
colleagues based on the CD44+/CD24− phenotype and
lack of ALDH [10]. It is also noteworthy that ΔNp63/
p40+ cancer cells localised at the periphery of tumour
cell islands in primary and locally metastatic patient
samples, the location of mesenchymal-like CSCs [10],
where stem cell activities require interactions with stro-
mal cells and/or microenvironmental factors that consti-
tute the CSC niche [13]. That MCF7 xenografts
showed a similar location provides additional evidence
for stromal influences on the induction or maintenance
of ΔNp63/p40 in these cells. Further evidence for a
CSC-like phenotype comes from the increase in
ΔNp63/p40 in mammosphere growth conditions that
enrich for CSC-like cells in cell lines and primary
tumours [39]. These observations complement previous
studies in which exogenous ΔNp63/p40 overexpression
promoted a variety of CSC-like properties in these cells
[17,18]. Unfortunately, due to the nuclear location of
ΔNp63/p40, we are unable to isolate live ΔNp63/p40+
cells to directly assess their mammosphere forming
ability or other CSC properties.
Although ΔNp63/p40 has pro-survival functions in
mammary stem/progenitor cells [40] and in basal/
HER2-driven experimental breast cancers [15,16], we
found that a ΔNp63/p40+ cell population was not
associated with poor patient survival in ER+ or HER2+
breast cancers, mirroring previous observations
[18,34]. In contrast, patients with HER2+ cancers con-
taining a ΔNp63/p40+ population had improved sur-
vival. Of note, these patient samples pre-date the
clinical use of trastuzumab. Other studies have shown
positive and negative associations between ΔNp63/p40
and HER2 (or other ERBB family members)
[18,23,40–42] and it is therefore likely that
HER2-ΔNp63/p40 crosstalk accounts for our observa-
tions. Investigation of ΔNp63/p40 as a marker of
improved prognosis deserves further study, potentially
in the setting of HER2 directed clinical trials. We also
note that our findings are relevant to daily diagnostic
routine, where scattered pan-p63+ or ΔNp63/p40+ cells
are sometimes seen and may represent a challenge to
report invasive breast cancer. In these rare doubtful
cases of ‘scattered’ versus ‘rim-like’ staining, the
potential that these cells represent ΔNp63/p40+ tumour
cells rather than myoepithelial cells should be consid-
ered and alternative markers (SMA, smooth muscle
myosin heavy chain or calponin) would be useful, with
the staining pattern being interpreted in the context of
the morphology.
It is worth noting that studies such as ours that iden-
tify rare subpopulations of cells within a tumour mass
are not possible using data from current array-based or
next-generation sequencing technologies, including
commercial prognostic breast cancer arrays, such as
OncotypeDX, MammaPrint, PAM50/Prosigna or
EndoPredict (reviewed in [43]). These targeted or non-
targeted transcriptomic approaches measure average
mRNA levels in tumour lysates and are unlikely to
identify rare cellular populations due to lack of sensi-
tivity within the overall transcriptome of the whole
tumour tissue. Moreover, it is not possible to perform
phenotypic analysis of individual cell populations from
average transcript levels in a tissue lysate. Thus, whilst
genomic, transcriptomic and proteomic data have been
extremely useful for identifying broad differences in
cancer sub-types and have prognostic value [43], they
hide single cell heterogeneity. As an important aside
of relevance to p63, array based data generally do not
identify alternative transcripts, so that the identification
of TP63 mRNA does not distinguish between TAp63
in lymphocytes, ΔNp63/p40 in myoepithelium or
ΔNp63/p40 in tumour cells. Thus, at the present time,
studies that identify and phenotype rare subpopulations
of heterogeneous cells require in situ approaches such
as immunohistochemistry. In the future, application of
single cell transcriptomics will be valuable, although
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even here the analysis of rare cell populations would
require data from thousands to millions of individual
cells.
In conclusion, ΔNp63/p40 is expressed by a small
subpopulation of cells in many ER+ and HER2+ human
breast cancers. That metastatic deposits do not have a
higher incidence of ΔNp63/p40+ cells argues against a
specific role in driving metastasis, corroborated by the
lack of correlation with clinical parameters including
node status. The phenotype and location of ΔNp63/
p40+ cells suggest that they represent basal/mesenchy-
mal-like rather than epithelial-like CSCs, identifying
ΔNp63/p40 as an additional marker of the phenotypic
heterogeneity of breast cancer cell populations [44].
Given the previous evidence that exogenous ΔNp63/
p40 induces stem/progenitor phenotypes in mammary
epithelial cells, including luminal-type cancer cells
in vitro [17,18], our demonstration of endogenous
ΔNp63/p40 in luminal cancers requires further study to
help understand breast cancer stem/progenitor cell
populations and provide additional avenues for thera-
peutic intervention.
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